LRRK2 G2019S mutation in Parkinson’s disease: A neuropsychological and neuropsychiatric study in a large Algerian cohort

Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene

“…This is in contrast to other studies of LRRK2 G2019S related PD were no difference has been found [4,5,29,30]; however, some differences between our and the mentioned studies should be highlighted. Firstly only the study of Belarbi et al [5] included a detailed cognitive testing; the other studies where either not primarily designed to detect differences in cognition and neuropsychiatric symptoms, or included only a very limited cognitive testing battery as in the case of the study of Ben Sassi et al [4]. Additionally both of these studies [4,5] were performed in populations with very low educational level and it results difficult to make a direct comparison with our study.…”

“…This study indicated M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT more frequent early cognitive impairment in the iPD group as compared to the mutation carriers [3]. This is in contrast to other studies of LRRK2 G2019S related PD were no difference has been found [4,5,29,30]; however, some differences between our and the mentioned studies should be highlighted. Firstly only the study of Belarbi et al [5] included a detailed cognitive testing; the other studies where either not primarily designed to detect differences in cognition and neuropsychiatric symptoms, or included only a very limited cognitive testing battery as in the case of the study of Ben Sassi et al [4].…”

“…Firstly only the study of Belarbi et al [5] included a detailed cognitive testing; the other studies where either not primarily designed to detect differences in cognition and neuropsychiatric symptoms, or included only a very limited cognitive testing battery as in the case of the study of Ben Sassi et al [4]. Additionally both of these studies [4,5] were performed in populations with very low educational level and it results difficult to make a direct comparison with our study. In the study by Alcalay et al no significant difference was found between the groups on a general cognitive test; however, there was a significant difference between the groups in terms of disease duration with the mutation carriers presenting longer disease duration.…”

“…Previous studies have indicated less or similar cognitive impairment in G2019S related PD when compared to idiopathic PD (iPD) patients [3,4]; however, some studies have indicated a possible higher prevalence of neuropsychiatric symptoms [5][6][7]. The published studies of PD related to mutations of the Ras of complex proteins GTPase domain of the LRRK2 gene (R1441C/G/H) have reported clinical features similar to those of G2019S related and idiopathic PD [8][9][10].…”

Parkinson's Disease in the Gulf Countries: An Updated Review

“…For example, not one study has stratified PD patients according to their cognitive state upon presentation/screening. The association of PD and cognitive decline may be of particular relevance to Arab patients, given that North African carriers of LRRK2 G2019S mutations were found to have higher rates of depression, hallucination and sleep disorders [17] .…”